Tysabri Articles
Elan tells shareholders it is worth up to $20.80 a share and they should not accept Royalty's $12.50 offer
30 May 2013
Elan reports 1st-qtr operating loss
24 April 2013
Elan plans $1 billion repurchase program post Tysabri deal closure
22 February 2013
Elan sells its Tysabri rights to Biogen; posts 2012 financials
7 February 2013
US multiple sclerosis market growth remains centered on Tysabri and Gilenya ahead of Aubagio's launch
28 September 2012
US neurologists' adoption of STRATIFY JCV has shifted Tysabri earlier in the treatment of some MS patients
15 August 2012
Elan back in the black, boosted by Tysabri
9 February 2012
FDA updates Tysabri label relating to anti-JCV
23 January 2012
Recent Gilenya growth appears to be coming from initial trial among late adopters not expanded use among existing prescribers
30 November 2011
Biogen Idec shares leap, as 1st-qtr 2011 earnings rocket, boosted by Tysabri; and by MS drug results
26 April 2011
Biogen Idec reports progress on New Framework for Growth
13 January 2011
European neurologists expect significant increases in the use of both Tysabri and Extavia in their multiple sclerosis patients
24 December 2010
Elan sees 3rd-qtr 2010 revenues slip 2%, and posts $43.6 million net loss; Tysabri partner Biogen Idec exceeds forecasts
28 October 2010
Nomura ups sales forecast for Novartis’s new oral MS drug Gilenya to $3.5 billion, as Biogen Idec says it is still confident about non oral products
24 September 2010
Uptake of the first oral MS therapies will result in the market value peaking at $8.4 billion in 2013
1 February 2010
EMEA proposes measures to better manage Tysabri’s PML risks; positive opinions from CHMP include two on GSK products
22 January 2010
Biogen Idec’s Tysabri surpasses $1 billion in 2009 sales; fampridine filed in EU, Canada; development deal with Trillium
13 January 2010
Does the MS market need another Interferon? US neurologists provide insight on the launch of Novartis’ Extavia
12 January 2010
Biogen Idec sees more cases of PML, as CEO departure is viewed as potential sale of the firm; new appointments made
11 January 2010
UK Department of Health’s “money back” deal for MS drugs questioned; failing people with the disease
3 December 2009
Biotech takes it on the chin in October
5 November 2009
Elan and Biogen hit by EU Tysabri questions
26 October 2009
US mid-caps Biogen, Forest and Gilead post in-line or better-than-expected three-month results
21 October 2009
Good news for Novartis’s MS drug fingolimod
1 October 2009
Elan cures breach of Tysabri deal and amends terms of transaction
15 September 2009
US court backs Biogen in fight with Elan over Tysabri
4 September 2009
Scientists show that BP drug lisinopril could have value in treating multiple sclerosis
19 August 2009
Elan in dispute with Biogen over Tysabri
7 August 2009
PDL expects 18% rise in 2nd-qtr revenues
9 June 2009
Elan appoints Renee Tannenbaum CCO
4 June 2009
PDL BioPharma swings to profit on cost-cuts
11 May 2009
Merck KGaA's 1st-qtr profit tumbles 76.3% to 56.7M euros on lower liquid crystal sales
27 April 2009
Elan 1st-qtr net loss widens 20% to $102.6M
27 April 2009
New case of PML will not bother Tysabri, says Zacks
22 April 2009
Biogen's 1st-qtr profit jumps 54% to $244M
20 April 2009
Stock Commentary - New York week to March 30, 2009
2 April 2009
Elan shares leap on Lundbeck rumors
27 March 2009
PDL returns to profit on sales up 31%
16 March 2009
Tysabri patients remain free of MS for two years
16 February 2009
Biogen Idec's full-year 2008 sales jump 33%
16 February 2009
Stock Commentary - New York week to Jan 19, 2009
26 January 2009
Lundbeck could be eyeing up Elan
26 January 2009
Elan takes on Citigroup to consider options
19 January 2009
Stock Commentary - Europe - week to Dec 15, 2008
22 December 2008
Elan drops 3.6% on new Tysabri PML case
22 December 2008
Elan to cut staff amid calls for CEO resignation
22 December 2008
Stock Commentary - Europe - week to Nov 10, 2008
17 November 2008
Elan's loss narrows further on Tysabri sales
10 November 2008
Biogen's 3rd-qtr EPS up 71% on drug sales
3 November 2008
Biogen Idec drops RA drug on poor Ph II data
20 October 2008
CHMP wants stronger Tysabri warning label
6 October 2008
Good results for Tysabri RMS trial
29 September 2008
Genentech/Biogen Idec's Rituxan linked to death of RA patient due to PML
22 September 2008
Biogen and Elan start testing Tysabri in first cancer setting with Ph I/II trial in MM
15 September 2008
Stock Commentary - Europe - week to Aug 25, 2008
1 September 2008
List of bidders shortens for Elan's EDT
1 September 2008
EMEA assessing data on Tysabri
18 August 2008
Stock Commentary - Europe - week to Aug 11, 2008
18 August 2008
Law suits stall awaiting FDA pre-emption verdict
18 August 2008
Stock Commentary - Europe - week to Aug 4, 2008
11 August 2008
Stock Commentary - New York week to Aug 4, 2008
11 August 2008
Tysabri sales improve Elan's 2nd-qtr loss 49%
4 August 2008
Biogen's 2nd-qtr 2008 revenue up 28%
4 August 2008
Elan looking to sell EDT unit for $1.5B?
28 July 2008
Stock Commentary - New York week to July 7, 2008
14 July 2008
PDL's 1st-qtr 2008 net loss triples to $62M
26 May 2008
Biogen Idec's 1st-qtr 2008 profit jumps 23%
5 May 2008
Stock Commentary - Europe - week to April 21, 2008
28 April 2008
Plasma exchange could address Tysabri PML profile
28 April 2008
Healthy worldwide uptake of Tysabri
28 April 2008
FDA starts safety review of Roche's CellCept and Novartis' Myfortic after cases of PML
21 April 2008
EMEA warns of liver injury with Tysabri
31 March 2008
Elan's 2007 loss up 51% on charges
25 February 2008
Biogen's 4th-qtr net income climbs 85%
14 February 2008
Stock Commentary - New York week to Feb 4, 2008
11 February 2008
Stock Commentary - New York week to Jan 7, 2008
14 January 2008
New data on Biogen/Elan's Tysabri
14 January 2008
Biogen ups 2007 income guide, on sales gains
14 January 2008
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
